<DOC>
	<DOCNO>NCT01410955</DOCNO>
	<brief_summary>Irinotecan one key drug use treatment colorectal cancer . The incidence irinotecan induce diarrhea varies 60-90 % , severe diarrhea 20-40 % . The main cause diarrhea one irinotecan metabolite , SN-38 liver glucuronidated subsequently expel intestine . Due bacterial enzyme beta-D-glucuronidase intestinal lumen deconjugated . This form cause direct damage intestinal mucosa associate malabsorption development diarrhea . It known probiotic bacteria , reduce activity intestinal beta-D-glucuronidase therefore bacteria could apply prevention diarrhea patient treat food supplement . Given low toxicity , good tolerability , probiotic may important part supportive therapy . This first study aim determine effectiveness probiotic prophylaxis irinotecan induced diarrhea due reduction intestinal beta-D-glucuronidase activity .</brief_summary>
	<brief_title>Prevention Irinotecan Induced Diarrhea Probiotics</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>sign write informed consent histologically proven colorectal cancer patient start new line chemotherapy base irinotecan ECOG PS 0 1 study entry life expectancy 3 month absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; impossibility take oral medication active infection treat antibiotic therapy ileostomy hypersensitivity study drug concurrent malignancy nonmelanoma skin cancer , cancer past 5 year . serious concomitant systemic disorder diseases incompatible study ( discretion investigator )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>probiotic</keyword>
	<keyword>diarrhoea</keyword>
	<keyword>prevention</keyword>
	<keyword>colon cancer</keyword>
	<keyword>irinotecan</keyword>
</DOC>